Connect with us

Press Release

Worldwide Respiratory Care Devices Industry to 2025

Published

on

DUBLIN, July 21, 2020 /PRNewswire/ — The “Respiratory Care Devices Market by Product (Therapeutic (Ventilator, Mask, PAP Device, Inhaler, Nebulizer), Monitoring (Pulse Oximeter, Capnograph), Diagnostic, Consumables), End-User (Hospital, Home Care), Indication – Global Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering.

The respiratory care devices market is expected to reach USD 29.86 billion by 2025, from USD 16.09 billion in 2019.

Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for respiratory care devices. Thus, the respiratory care devices market witnessed a CAGR of 261.1% between 2019 and 2020. In 2020, the respiratory care devices market reached USD 58.1 billion. The growth of this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidence of preterm births, and lifestyle changes. However, a lack of awareness-leading to a large underdiagnosed and undertreated population and the harmful effects of specific respiratory care devices on neonates have hampered market growth to an extent.

COPD was the largest and fastest-growing indication of respiratory care devices market in 2019.

COPD is a medical term referring to a group of lung diseases, including chronic bronchitis and emphysema. It is an inflammatory and progressive life-threatening lung disease characterized by a persistent blockage of airflow from the lungs. One of the major causes of COPD is tobacco smoking. According to the US CDC, as many as eight in 10 COPD-related deaths are due to smoking. Additionally, rising indoor (biomass fuel) and outdoor air pollution levels, exposure to dust and chemicals (vapors, irritants, and fumes), genetic disorders, and increasing geriatric population are other factors driving the prevalence of COPD. The elements, as mentioned above, are expected to drive the demand for respiratory care devices during the forecast period.

Hospitals are the largest end-user segment in the respiratory care devices market in 2019

Based on end-user, the respiratory care devices market is divided into hospitals, home care settings, and ambulatory care. Hospitals form the largest end-user segment of the respiratory care devices market. This can largely be attributed to the financial capabilities of hospitals to purchase expensive equipment and the availability of trained professionals in hospitals to operate respiratory care devices. Hospitals provide respiratory care services to patients through various departments, such as intensive care units, emergency rooms, outpatient departments, and pulmonary diagnostic laboratories, among others. Moreover, COVID-19 has tremendously impacted o the hospital segment. Several hospitals have been established in order to cure an increasing number of patients infected from the coronavirus.

North America will continue to dominate the respiratory care devices market in 2025

The respiratory care devices market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2019, North America accounted for the largest share of the respiratory care devices market. The large share of North America in this market can be attributed to the outbreak of COVID-19, which has driven the demand for respiratory devices in North America. Due to its growing geriatric population segment and environmental conditions that have favored the spread of the disease, COVID-19 has severely affected the region and ensured enormous growth in the demand for respiratory care devices. Players in this and adjacent, or even non-related, markets have focused on or collaborated for expanding the manufacturing of critical care instruments and respiratory care devices.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Respiratory Care Devices Market: Market Overview
4.2 North America: Respiratory Care Devices Market, 2019
4.3 Respiratory Care Devices Market: Geographic Growth Opportunities
4.4 Respiratory Care Devices Market: Geographic Mix
4.5 Respiratory Care Devices Market: Developing Vs. Developed Markets

5 Market Overview
5.1 Introduction
5.2 Market Drivers
5.2.1 Rising Prevalence of Respiratory Diseases
5.2.1.1 Rapid Growth in the Global Geriatric Population
5.2.1.2 Urbanization and Growing Pollution Levels
5.2.1.3 High Prevalence of Tobacco Smoking
5.2.1.4 Changing Lifestyles
5.2.2 Increasing Incidence Rate of Preterm Births
5.2.2 Outbreak of Infectious Diseases Affecting Respiratory System
5.3 Market Restraints
5.3.1 Unfavorable Reimbursement Scenario
5.3.2 Availability of Low-Cost Products From Local Manufacturers
5.4 Market Opportunities
5.4.1 Growing Demand for Home Care therapeutic Devices
5.4.2 High Growth in Developing Countries Across APAC and Latin America
5.4.3 Point-of-Care Diagnostics – an Upcoming Opportunity
5.5 Market Challenges
5.5.1 Low Awareness and Large Underdiagnosed and Undertreated Population
5.5.2 Harmful Effects of Certain Devices on Neonates

6 Industry Trends
6.1 Rising Demand for Enhanced Portable & Compact Devices
6.2 Focus of Market Players on Expanding Their Geographical Presence
6.3 Growing Demand for Multimodal Ventilation
6.4 Rising Adoption of Noninvasive Ventilation
6.5 Technology Trends
6.5.1 E-Nose Technology
6.5.2 Wireless Gas Sensor Technology
6.5.3 Artificial Intelligence for Personalized Requirements

7 Respiratory Care Devices Market, By Product
7.1 Introduction
7.2 Therapeutic Devices
7.3 Monitoring Devices
7.4 Diagnostic Devices
7.5 Consumables & Accessories

8 Respiratory Care Devices Market, By Indication
8.1 Introduction
8.2 Chronic Obstructive Pulmonary Disease (Copd)
8.2.1 Increasing Prevalence of Copd to Drive the Demand for Respiratory Care Devices
8.3 Sleep Apnea
8.3.1 Rising Awareness About Diagnosis of Sleep Apnea to Drive Demand for Respiratory Care Devices
8.4 Asthma
8.4.1 Increasing Global Burden of Asthma to Support Market Growth
8.5 Infectious Diseases
8.5.1 Rising Awareness for Tb Diagnosis to Drive Market Growth
8.6 Other Indications

9 Respiratory Care Devices Market, By End User
9.1 Introduction
9.2 Hospitals
9.2.1 This Segment Held the Largest Share of the Respiratory Care Devices Market in 2018
9.3 Home Care Settings
9.3.1 Technological Advancements Have Led to the Development of Compact & Lightweight Respiratory Care Devices That are Easy to Carry and Operate
9.4 Ambulatory Care Centers
9.4.1 There is A Shift in Patient Preference From Extended Hospital Treatment towards Treatment at Accs

10 Respiratory Care Devices Market, By Region
10.1 Introduction
10.2 North America
10.3 Europe
10.4 Asia Pacific
10.5 Latin America

11 Competitive Landscape
11.1 Introduction
11.2 Geographical Assessment of the Major Players in the Respiratory Care Devices Market
11.3 Competitive Situations and Trends
11.3.1 Product Launches
11.3.2 Expansions
11.3.3 Acquisitions
11.3.4 Agreements and Partnerships
11.4 Competitive Assessment of R&D Expenditure
11.5 Market Share Analysis
11.6 Competitive Leadership Mapping
11.6.1 Visionary Leaders
11.6.2 Innovators
11.6.3 Dynamic Differentiators
11.6.4 Emerging Companies

12 Company Profiles
12.1 Philips Healthcare
12.1.1 Business Overview
12.1.2 Products offered
12.1.3 Recent Developments
12.2 Resmed, Inc.
12.3 Medtronic Plc
12.4 Masimo Corporation
12.5 Fisher and Paykel Healthcare Co., Ltd.
12.6 Getinge Ab
12.7 Air Liquide
12.8 Drgerwerk Ag & Co. Kgaa
12.9 Hamilton Medical Ag
12.10 Invacare Corporation
12.11 Vyaire Medical
12.12 Nihon Kohedon Corporation.
12.13 General Electric.
12.14 Apex Medical Corporation.
12.15 Teleflex Incorporated.
12.16 Nonin.
12.17 Allied Healthcare Products, Inc.
12.18 Smiths Medical, Inc.
12.19 Drive Devilbiss Healthcare.
12.20 Omron Healthcare, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1j0ih

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.


Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

This story has been sourced from a third party syndicated feed, agencies. News Galiyara accepts no responsibility or liability for its dependability, trustworthiness, reliability, and data of the text. DigitalGaliyara (OPC) Private Limited management reserves the sole right to alter, delete or remove (without notice). If you have any concerns with the Content, then please write to us at the mail@digitalgaliyara.com Source – PRNewsWire

Press Release

The Pressing Need for Early Detection of Mucormycosis during COVID-19

Published

on

Fapon Biotech calls for cooperation with academic and industry partners in developing mucormycosis diagnostic tests to ease the challenge by sharing the abilities of upstream raw material development platforms and downstream reagent application platforms.

DONGGUAN, China, June 21, 2021 /PRNewswire/ — Mucormycosis or black fungus, a devastating infection that soars in India during COVID-19 has seized global attention. Recently, the country’s mucormycosis cases reached over 57,150 and resulted in 54% mortality. Apart from the association with high diabetes prevalence in India, COVID-19 infected countries (Pakistan, Russia, Nepal, Chile, Brazil, etc.) have also described the same issue, areas with high diabetes and COVID-19 infection rates should be alarmed.

Fapon Biotech calls for cooperation with academic and industry partners in developing mucormycosis diagnostic tests to ease the challenge by sharing the abilities of upstream raw material development platforms and downstream reagent application platforms.

Unfortunately, mucormycosis is always being diagnosed late with prolonged COVID-19 healthcare burdens that deteriorate the situation. As a company making continuous research and contribution to the world’s major infectious diseases with the mission to Enable Disease Identification Earlier, More Accurate, Convenient and Affordable, Fapon Biotech Inc. (Fapon Biotech) calls for cooperation with academic and industry partners in developing mucormycosis diagnostic tests to ease the challenge by sharing the abilities of upstream raw material development platforms and downstream reagent application platforms.

Fapon Biotech is one of the mainstream COVID-19 reagent raw material suppliers with proven experiences helping partners to launch accredited COVID-19 reagents in a short time. The company has over 1000 IVD partners worldwide with more than 10 years of business operation in India. Its technology platforms can match the R&D process from partners easily and provide supports from biomarker discovery to commercialization. Through different application platforms of Fapon Biotech (Colloidal Gold/Immunofluorescence/ELISA/CLIA/Latex-Enhanced Immunoturbidimetry/PCR/etc.), biomarkers can quickly complete the process of application development. For partners encountering production challenges, OEM and contract manufacturing services with the capacity reaching hundreds of grams of each batch are available. Because of a strong relationship with laboratories and IVD manufacturers in India, cooperating with Fapon Biotech will have the access to more resources and commercial opportunities, such as clinical samples for research and product validation, technology iterations, product launch and promotion, etc.

As the virus continues its mutation and triggers diseases like mucormycosis to complicate the situation, rapid responses via global cooperation will be crucial for areas with overwhelmed healthcare burdens. Fapon Biotech is committed to fueling the advancement of COVID-19 diagnosis through collaborations with international IVD partners.

About Fapon Biotech

Fapon Biotech was founded in 2001. Guided by the mission of “Enable Disease Identification Earlier, More Accurate, Convenient and Affordable,” the company focuses on the future needs of biotechnology developments and provides global diagnostic companies with high-performance IVD reagent raw materials, such as antigens, antibodies, and enzymes, as well as one-stop solutions with instrument and reagent services.

Photo – https://mma.prnewswire.com/media/1537054/Fapon_Biotech.jpg

Continue Reading

Press Release

RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19

Published

on

RedHill Biopharma logo

Positive U.S. Phase 2 safety and efficacy data for opaganib, a leading novel, oral, dual-mechanism drug candidate for moderate-to-severe COVID-19, presented at the World Microbe Forum

Opaganib was associated with a reduction in the need for supplemental oxygen support, earlier time to discharge from hospital and was well tolerated

Opaganib’s global 475-patient Phase 2/3 study is fully enrolled, with study completion expected in the coming weeks

Opaganib is host-targeted and expected to be effective against emerging viral variants

TEL AVIV, Israel and RALEIGH, NC, June 21, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021 (poster #: 5574).

RedHill Biopharma logo

Results and post hoc analyses of data from the 40-patient U.S. Phase 2 study were presented in a poster entitled, “Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618)“[2]. Patients in the study were randomized to receive either opaganib or placebo in addition to standard of care (SoC), predominantly including dexamethasone and/or remdesivir. Findings include:

  • 50% of patients treated with opaganib (n=22) reached room air by Day 14 compared to 22% in the placebo group (n=18). The benefit of reaching room air by Day 14 for patients on opaganib was maintained regardless of whether the patients were receiving dexamethasone and/or remdesivir
  • 86.4% of patients treated with opaganib were discharged from hospital by Day 14 compared to 55.6% of patients treated with placebo
  • Median time to discharge was 6 days for the opaganib group compared to 7.5 days for the placebo group
  • 81.8% of opaganib patients achieved a 2-point improvement in the WHO Ordinal Scale compared to 55.6% of patients in the placebo group – achieved in a median time of 6 days versus 7.5 days, respectively
  • No significant differences in safety-related measures between the two groups (with diarrhea being the main treatment-emergent difference in tolerability)

“The need for an effective oral therapy to treat COVID-19 is clear. Such a therapy would greatly improve our ability to manage this pandemic,” said Kevin Winthrop, MD, MPH, Professor of Infectious Diseases at Oregon Health & Science University, who presented the findings at WMF. “These data, from this proof-of-concept clinical study of opaganib in patients with severe COVID-19, suggest a potential role of SK2 inhibition in combating the effects of this virus. With much more data on opaganib expected in the coming weeks, we could make some real progress toward having access to a much-needed oral therapy for patients who currently have a paucity of options available to them.”

“Presentation of these positive data from our exploratory Phase 2 study support our growing confidence that opaganib could be the first novel, oral therapy to demonstrate efficacy in the treatment of COVID-19 in a large late-stage study. With the recent completion of enrollment of our 475-patient global Phase 2/3 study, we will have a clearer picture of that in the very near future,” said Mark L. Levitt, MD, Ph.D., Medical Director at RedHill. “Opaganib acts on both the cause and effect of COVID-19 via a unique dual antiviral and anti-inflammatory mode of action. Being host-targeted, opaganib is also expected to maintain effect against the emerging SARS-CoV-2 variants, which continue to threaten the progress being made against the pandemic and underscore the urgent need for effective COVID-19 therapeutics.”

The global 475-patient Phase 2/3 study of opaganib in severe COVID-19 has been approved in 10 countries and completed enrollment, through 57 participating sites, on June 6th. The primary endpoint of the study is the proportion of patients breathing room air without oxygen support by Day 14. Additional important outcome measures, such as time to discharge from hospital, improvement according to the World Health Organization Ordinal Scale for Clinical Improvement and incidence of intubation and mortality, will also be captured in the follow-up period of up to 6 weeks. The study received four independent DSMB recommendations to continue following unblinded safety reviews and a futility review. Additionally, an evaluation of the blinded blended intubation and mortality rates to date was encouraging as compared to reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations[3].

About Opaganib (Yeliva®, ABC294640)

Opaganib, a new chemical entity, is a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2) selective inhibitor, with dual anti-inflammatory and antiviral activity, that is host-targeted and is therefore expected to be effective against emerging viral variants. Opaganib has also shown anticancer activity and has the potential to target multiple oncology, viral, inflammatory, and gastrointestinal indications.

Opaganib is being evaluated as a treatment for COVID-19 pneumonia in a global Phase 2/3 study, which recently completed enrollment, and has demonstrated positive safety and efficacy signals in preliminary top-line data from the 40-patient U.S. Phase 2 study.

Opaganib has also received Orphan Drug designation from the U.S. FDA for the treatment of cholangiocarcinoma and is being evaluated in a Phase 2a study in advanced cholangiocarcinoma and in a Phase 2 study in prostate cancer.

Opaganib demonstrated potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19, completely inhibiting viral replication in an in vitro model of human lung bronchial tissue. Additionally, preclinical in vivo studies have demonstrated opaganib’s potential to ameliorate inflammatory lung disorders, such as pneumonia, and has shown decreased fatality rates from influenza virus infection and ameliorated Pseudomonas aeruginosa-induced lung injury by reducing the levels of IL-6 and TNF-alpha in bronchoalveolar lavage fluids[4].

The ongoing studies with opaganib are registered on www.ClinicalTrials.gov, a web-based service by the U.S. National Institute of Health, which provides public access to information on publicly and privately supported clinical studies.   

About RedHill Biopharma    

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs, Movantik® for opioid-induced constipation in adults[5], Talicia® for the treatment of Helicobacter pylori (H. pylori) infection in adults[6], and Aemcolo® for the treatment of travelers’ diarrhea in adults[7]. RedHill’s key clinical late-stage development programs include: (i) RHB-204, with an ongoing Phase 3 study for pulmonary nontuberculous mycobacteria (NTM) disease; (ii) opaganib (Yeliva®, ABC294640), a firstinclass SK2 selective inhibitor targeting multiple indications with positive Phase 2 COVID-19 data and an ongoing Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii) RHB-107 (upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv) RHB-104, with positive results from a first Phase 3 study for Crohn’s disease; (v) RHB-102 (Bekinda®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi) RHB106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.         

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include the delay in last patient visit and top-line data from the Phase 2/3 COVID-19 study for opaganib, that the Phase 2/3 COVID-19 study for opaganib may not be successful and, even if successful, such study and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib are likely to be required by regulatory authorities to support such potential applications and the use or marketing of opaganib for COVID-19 patients, that opaganib will not be effective against emerging viral variants, as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company’s research, manufacturing, preclinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company’s ability to advance its therapeutic candidates into clinical trials or to successfully complete its preclinical studies or clinical trials (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company’s receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company’s therapeutic candidates and Talicia®; (v) the Company’s ability to successfully commercialize and promote Movantik®, Talicia® and Aemcolo®; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) the Company’s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build and sustain its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company’s therapeutic candidates and the results obtained with its therapeutic candidates in research, preclinical studies or clinical trials; (ix) the implementation of the Company’s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and commercial products and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company’s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse events using investigative drugs under the Company’s Expanded Access Program; and (xiv) competition from other companies and technologies within the Company’s industry. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on March 18, 2021. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.

 

Company contact:

Adi Frish

Chief Corporate & Business Development Officer

RedHill Biopharma

+972-54-6543-112

adi@redhillbio.com

Media contacts:

U.S.: Bryan Gibbs, Finn Partners

+1 212 529 2236

bryan.gibbs@finnpartners.com

UK: Amber Fennell, Consilium

+44 (0) 7739 658 783  

fennell@consilium-comms.com

 

[1] Opaganib is an investigational new drug, not available for commercial distribution.

[2] Opaganib, an Oral Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia: A Randomized, Double-blind, Placebo-controlled Phase 2A Study, in Adult Subjects Hospitalized with SARS-CoV-2 Positive Pneumonia (NCT: 04414618). K. L. Winthrop, A. W. Skolnick, A. M. Rafiq, S. H. Beegle, J. Suszanski, G. Koehne, O.Barnett-Griness, A. Bibliowicz, R. Fathi, P. Anderson, G. Raday, G. Eagle, V. Katz Ben-Yair, H. S. Minkowitz, M. L. Levitt, M. S. Gordon

[3] Based on preliminary blinded blended data from 463 patients. The Company did not conduct a head-to-head comparison study in the same patient population. The theoretical comparison between the global Phase 2/3 study with opaganib and reported rates of mortality from large platform studies such as RECOVERY, and other studies in similar patient populations, serves as a general benchmark and should not be construed as a direct and/or applicable comparison as if the Company conducted a head-to-head comparison study.

[4] Xia C. et al. Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice. Antiviral Res. 2018 Oct; 158:171-177. Ebenezer DL et al. Pseudomonas aeruginosa stimulates nuclear sphingosine-1-phosphate generation and epigenetic regulation of lung inflammatory injury. Thorax. 2019 Jun;74(6):579-591.

[5] Full prescribing information for Movantik® (naloxegol) is available at: www.Movantik.com.  

[6] Full prescribing information for Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is available at: www.Talicia.com.       

[7] Full prescribing information for Aemcolo® (rifamycin) is available at: www.Aemcolo.com.

Logo – https://mma.prnewswire.com/media/1334141/RedHill_Biopharma_Logo.jpg

 

 

Continue Reading

Press Release

Pandora Boosts Online Sales by Transforming Its Global Omnichannel e-Commerce with IBM Sterling Supply Chain Software

Published

on

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

One of the world’s largest jewelry brands by volume uses IBM Sterling Order Management on Cloud to revamp its fulfillment capabilities and customer experience

ARMONK, N.Y., June 21, 2021 /PRNewswire/ — IBM (NYSE: IBM) has worked with Pandora (NASDAQ: PNDORA), a leading designer, manufacturer and marketer of hand-finished jewelry, to help Pandora transform and scale its global omnichannel e-commerce capabilities with IBM Sterling Order Management. Pandora, one of the world’s largest jewelry brands, was able to double its online sales in 2020 and is now leading the jewelry industry with improved real-time inventory visibility to better manage growing demand.

Pandora, a leading designer, manufacturer and marketer of hand-finished jewelry, is using IBM Sterling Order Management for improved real-time inventory visibility. Photo courtesy Pandora.

Pandora’s focus on innovating new customer experiences included using IBM Sterling Order Management to help to increase the company’s supply chain resiliency and business agility, and better mitigate disruptions and risk. By automating more of their order orchestration across channels, they also have opportunity to improve the sustainability and resiliency of their supply chain operations with more efficient delivery.

“Over the past couple of years, Pandora has made significant investments in digital capabilities and data, and we have consolidated, simplified and modernized the technology stack to bring digital and store technology closer together and closer to the customer,” said Jim Cruickshank, VP of Digital Development & Retail Technology, Pandora. “Our mission is about creating a personal experience and we’ve instituted massive platform changes with IBM Sterling and Salesforce to enable new digital-first capabilities that are much more individualized, localized and connected across channels and markets.”

Pandora’s entry into e-commerce over the last six years most recently led them to consolidate legacy technologies while deploying the new order management solution across its key markets. Using IBM Sterling Order Management as its backend for omnichannel fulfillment and Salesforce Commerce Cloud for e-commerce, Pandora created a seamless shopping experience across channels. By automating order orchestration processes, store associates and virtual customer service representatives are able to have an end-to-end view across inventory, order and delivery status to help meet consumer expectations.

To support this ambitious objective, Pandora established a Digital Hub in Copenhagen, Denmark, with dedicated digital, data and tech teams that have played a vital role in the solution’s quick deployment entirely remotely. As the pandemic forced Pandora to temporarily close most of its 2,700 stores, the digital investments in supply chain efficiency helped fuel the company’s e-commerce success. In addition to some of the go-to fulfillment options many retailers offered such as buy online pickup in store (BOPIS) and endless aisle, Pandora also introduced more innovative approaches such as virtual queuing for stores and AR-based virtual trials of products to help drive more immersive customer engagement.

“The global disruption every industry experienced as all forms of commerce were severely impacted by the pandemic was especially challenging for organizations with disconnected distributed order management systems and limited scalability,” said Jordan Speer, Research Manager – Global Supply Chain, IDC Retail Insights. “This vulnerability created a push to more quickly advance technology adoption that helps retailers better respond to fluctuating consumer dynamics. To meet this changing demand, enterprises are looking to harness new tools to achieve increased levels of supply chain resilience and efficiency while also allowing for more virtual interactions.”

Pandora’s detailed view on order and order lines as well as near real-time inventory management helped to improve insights throughout their systems chain spanning warehouse management solutions, e-commerce and customer contact center. This was further enabled with increased automation from self-service capabilities and the use of chatbots aiding customer support functions as Pandora experienced a massive increase in order volumes.

“The lifeblood of the global economy, consumer behavior, has significantly shifted and will continue to evolve with businesses needing to quickly adapt to new preferences and needs. To address this shift, leading retailers like Pandora rely on innovation to increase their business agility by enabling and scaling sustainable supply chain operations using AI and cloud,” said Kareem Yusuf, General Manager, AI Applications and Blockchain, IBM. “Pandora’s experience shows that they can stay competitive as business and technology leaders are finding new ways to create differentiated customer experiences that protect their enterprises from disruptions to help mitigate risk and accelerate growth.”

To hear more about Pandora’s omnichannel experience using IBM Sterling Order Management view their THINK 2021 keynote detailing how they continue to execute on their strategic initiatives by navigating one of the world’s greatest supply chain disruption.

About Pandora

Pandora designs, manufactures and markets hand-finished jewelry made from high-quality materials at affordable prices. Pandora jewellery is sold in more than 100 countries through more than 6,700 points of sale, including around 2,700 concept stores.

Headquartered in Copenhagen, Denmark, Pandora employs 26,000 people worldwide and crafts its jewelry at two LEED certified facilities in Thailand using mainly recycled silver and gold. The company plans to be carbon neutral by 2025 and has joined the Science Based Targets initiative to reduce emissions across its full value chain. Pandora is listed on the Nasdaq Copenhagen stock exchange and generated sales of DKK 19.0 billion (EUR 2.5 billion) in 2020.

About IBM Sterling Supply Chain

IBM Sterling Supply Chain solutions empower IT and supply chain professionals with greater visibility, transparency and trust to proactively predict and mitigate disruption, improve B2B information flow, and optimize inventory utilization and fulfillment. Learn how our AI- and blockchain-enabled solutions help you build an intelligent, self-correcting supply chain at www.ibm.com/supply-chain.

Contacts:

Heli Koenkyto

Heli.Koenkyto@ibm.com

Erik Mason

erik.mason@ibm.com

IBM Corporation logo.

Photo – https://mma.prnewswire.com/media/1536971/IBM_Sterling_Pandora_mobile.jpg

Logo – https://mma.prnewswire.com/media/95470/ibm_logo.jpg

Continue Reading

Trending